Tag: European Medicines Agency
European Medicines Agency reviews safety of alemtuzumab
EMA conducts safety review of alemtuzumab (Lemtrada)
Daclizumab withdrawn from market over safety concerns
European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS